Brind.

Stifel reiterated a 'Buy' rating on Alto Neuroscience (ANRO) on July 29, 2025.

1 report, 1 independent Updated Jul 29

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Alto Neuroscience (United States)Stifel

Keep exploring

The entities involved

Alto Neuroscience (United States)
company in Los Altos, United States

Nothing else this week.
Stifel
American investment bank
- China and Stifel are currently top suppliers in the critical minerals market, with their market actions showing a preference for producers located outside of China.Mon 00:03
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.Sun 01:33

Related events

Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.Sep 1

Coverage

Newest first; wire copies grouped

Jul 29Insider MonkeyStifel Keeps Buy Rating on Alto Neuroscience (ANRO) Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its “Buy” rating on Alto